Q-omics provides the consensus-scored POTEB2 profile across patient tissues and cancer cell-line models. POTEB2 expression is associated with patient survival in 4 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, POTEB2 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, POTEB2 RNA expression shows 747 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight STAD, and BRCA as cancer lineages where POTEB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTEB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTEB2 survival associations across molecular data types. POTEB2 RNA expression shows survival associations in the most cancer types (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTEB2 RNA expression–survival associations across cancer types. High POTEB2 expression shows unfavorable associations in STAD, SKCM, ESCA and GBM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for POTEB2 RNA expression.
This table summarizes POTEB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for POTEB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTEB2 shows higher tumor expression in BRCA. The BRCA box plot shows higher POTEB2 RNA expression in tumor versus normal tissue (log2 FC = +0.002, t-test p = .044).
This table shows molecular features associated with POTEB2 in patient tissues and cancer cell lines. In patient samples, POTEB2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, POTEB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
